Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer
09:01am, Tuesday, 16'th Feb 2021
Exelixis Inc (NASDAQ: EXEL) has reported new data from the Phase 2 (PAPMET) study evaluating CABOMETYX (cabozantinib) compared with Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in patients with
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 2 results for CABOMETYX® (cabozantinib) compared with sunitinib, the current preferred therapy according
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including s
Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss
03:52pm, Thursday, 11'th Feb 2021
Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.
Exelixis' (EXEL) CEO Mike Morrissey on Q4 2020 Results - Earnings Call Transcript
01:03am, Thursday, 11'th Feb 2021
Exelixis' (EXEL) CEO Mike Morrissey on Q4 2020 Results - Earnings Call Transcript
Recap: Exelixis Q4 Earnings
04:40pm, Wednesday, 10'th Feb 2021
Shares of Exelixis (NASDAQ:EXEL) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 46.15% over the past year to $0.14, which beat the
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Sympo
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced results from a retrospective analysis evaluating CABOMETYX® (cabozantinib) activity in brain metastases in patients wit
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
10:37am, Monday, 08'th Feb 2021
Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
03:38pm, Sunday, 07'th Feb 2021
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
Got $4,000? 4 Growth Stocks Begging to Be Bought
05:51am, Friday, 29'th Jan 2021
Growth stocks have run circles around value stocks for more than a decade, and that trend is likely to continue.
Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021
04:05pm, Wednesday, 27'th Jan 2021
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2020 financial results will be released on Wednesday, February 10, 2021 after the
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
10:32am, Monday, 25'th Jan 2021
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced initiation of the first-in-human phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary ant
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
07:44pm, Friday, 22'nd Jan 2021
The regulator's nod represents an important expansion for the drug.
